Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
September 28, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months Chemistry optimization yields a four-fold increase over PBS control in AAT...
Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
September 22, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
September 09, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and...
Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
September 08, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
September 07, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 07:30 ET
|
Wave Life Sciences USA, Inc.
Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in...
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021
July 26, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
July 20, 2021 08:00 ET
|
Wave Life Sciences USA, Inc.
First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of...
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
June 02, 2021 16:52 ET
|
Wave Life Sciences USA, Inc.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating...